Chemoinformaics analysis of NCNUKSMLRPTJBC-NXTBLZEOSA-
| Molecular Weight | 438.429 | nRot | 4 |
| Heavy Atom Molecular Weight | 412.221 | nRig | 22 |
| Exact Molecular Weight | 438.153 | nRing | 4 |
| Solubility: LogS | -2.583 | nHRing | 2 |
| Solubility: LogP | -0.731 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 57 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 31 | No. of Aromatic Carbocycles | 0 |
| nHetero | 10 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 21 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 10 | No. of Arom Bond | 0 |
| nHA | 10 | APOL | 60.4266 |
| nHD | 5 | BPOL | 33.0274 |
| QED | 0.364 |
| Synth | 4.844 |
| Natural Product Likeliness | 1.837 |
| NR-PPAR-gamma | 0.286 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.997 |
| HIA | 0.884 |
| CACO-2 | -5.962 |
| MDCK | 0.000049 |
| BBB | 0.269 |
| PPB | 0.792817 |
| VDSS | 1.122 |
| FU | 0.182975 |
| CYP1A2-inh | 0.007 |
| CYP1A2-sub | 0.068 |
| CYP2c19-inh | 0.005 |
| CYP2c19-sub | 0.662 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.471 |
| CYP2d6-inh | 0 |
| CYP2d6-sub | 0.14 |
| CYP3a4-inh | 0.005 |
| CYP3a4-sub | 0.03 |
| CL | 1.384 |
| T12 | 0.303 |
| hERG | 0.005 |
| Ames | 0.68 |
| ROA | 0.427 |
| SkinSen | 0.063 |
| Carcinogencity | 0.188 |
| EI | 0.007 |
| Respiratory | 0.035 |
| NR-Aromatase | 0.929 |
| Antiviral | Yes |
| Prediction | 0.757909 |